Yong-Chul Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7908731/publications.pdf

Version: 2024-02-01

112	2,710	186265	223800
papers	citations	28 h-index	46 g-index

114	114	114	3812
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 55, 128451.	2.2	1
2	Discovery of substituted indole derivatives as allosteric inhibitors of<scp>m⁶Aâ€RNA</scp>methyltransferase,<scp>METTL3</scp>â€14 complex. Drug Development Research, 2022, , .	2.9	9
3	Synthesis and Structureâ€“Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents. Molecules, 2022, 27, 1337.	3.8	4
4	Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain. Pharmaceuticals, 2022, 15, 407.	3.8	0
5	Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the m6A Methylation of RNA in Acute Myeloid Leukemia Cells. Pharmaceuticals, 2022, 15, 440.	3.8	24
6	Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A2B adenosine receptor antagonists. Biochemical Pharmacology, 2022, 200, 115027.	4.4	3
7	Discovery of indirubin-3â€²-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia. European Journal of Medicinal Chemistry, 2022, 237, 114356.	5.5	1
8	Discovery of 5-methyl-1H-benzo[d]imidazole derivatives as novel P2X3 Receptor Antagonists. Bioorganic and Medicinal Chemistry Letters, 2022, , 128820.	2.2	0
9	Abstract 5445: New discovery and development of transglutaminase 2 inhibitor. Cancer Research, 2022, 82, 5445-5445.	0.9	0
10	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation. Bioorganic and Medicinal Chemistry, 2022, 68, 116862.	3.0	2
11	AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists. European Journal of Medicinal Chemistry, 2022, 240, 114556.	5.5	6
12	Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer. Pharmaceuticals, 2021, 14, 38.	3.8	5
13	Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents. Journal of Medicinal Chemistry, 2021, 64, 5500-5518.	6.4	7
14	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives. Journal of Medicinal Chemistry, 2021, 64, 8272-8286.	6.4	21
15	Indirubin-3-monoxime Prevents Tumorigenesis in Breast Cancer through Inhibition of JNK1 Activity. Biomedical Science Letters, 2021, 27, 134-141.	0.3	3
16	Development of UHPLC-MS/MS Method for Indirubin-3â€²-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats. Molecules, 2020, 25, 2039.	3.8	1
17	Discovery of orally active indirubin-3â€²-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. European Journal of Medicinal Chemistry, 2020, 195, 112205.	5.5	21
18	Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Scientific Reports, 2019, 9, 11587.	3.3	37

#	Article	IF	Citations
19	Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects. Biomolecules and Therapeutics, 2019, 27, 216-221.	2.4	10
20	Discovery of Novel Biased Opioid Receptor Ligands through Structureâ€Based Pharmacophore Virtual Screening and Experiment. ChemMedChem, 2019, 14, 1783-1794.	3.2	5
21	Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819. Data in Brief, 2019, 25, 104373.	1.0	4
22	A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity. Bioorganic and Medicinal Chemistry, 2019, 27, 2923-2934.	3.0	8
23	Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nature Communications, 2019, 10, 2184.	12.8	41
24	Discovery of LDDâ€‘1075 as a potent FLT3 inhibitor. Oncology Letters, 2019, 17, 4735-4741.	1.8	1
25	Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. European Journal of Medicinal Chemistry, 2018, 151, 462-481.	5.5	24
26	Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7â€“NMDA Receptor Antagonists. Molecules, 2018, 23, 230.	3.8	20
27	Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and â€“ pyrimidines. European Journal of Medicinal Chemistry, 2018, 155, 406-417.	5.5	34
28	Mapping of cutaneous melanoma by femtosecond laser-induced breakdown spectroscopy. Journal of Biomedical Optics, 2018, 24, 1.	2.6	20
29	Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. Oncotarget, 2018, 9, 924-936.	1.8	11
30	Escape from adamantane: Scaffold optimization of novel P2X7 antagonists featuring complex polycycles. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 759-763.	2.2	11
31	ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. Scientific Reports, 2017, 7, 44186.	3.3	42
32	Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors. ACS Chemical Neuroscience, 2017, 8, 1465-1478.	3.5	24
33	Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity. Investigational New Drugs, 2017, 35, 733-741.	2.6	6
34	Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor. Oncology Letters, 2017, 14, 1347-1354.	1.8	2
35	P2X7 receptor antagonists: a patent review (2010â€“2015). Expert Opinion on Therapeutic Patents, 2017, 27, 257-267.	5.0	84
36	Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells. Immune Network, 2017, 17, 110.	3.6	11

#	Article	IF	Citations
37	Validation of a liquid chromatographyâ€triple quadrupole mass spectrometric method for the determination of 5â€nitroâ€5â€²â€hydroxyâ€indirubinâ€3â€²â€oxime (AGMâ€130) in human plasma and its application to microdose clinical trial. Biomedical Chromatography, 2016, 30, 323-329.	1.7	4
38	Subdermal Flexible Solar Cell Arrays for Powering Medical Electronic Implants. Advanced Healthcare Materials, 2016, 5, 1572-1580.	7.6	112
39	Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-Î² during Murine Colitis. Cell Reports, 2016, 17, 3219-3232.	6.4	116
40	2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors. European Journal of Medicinal Chemistry, 2016, 120, 202-216.	5.5	16
41	Elemental analysis of tissue pellets for the differentiation of epidermal lesion and normal skin by laser-induced breakdown spectroscopy. Biomedical Optics Express, 2016, 7, 1626.	2.9	6
42	Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2719-2723.	2.2	26
43	Discovery and structureâ€“activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents. Bioorganic and Medicinal Chemistry, 2016, 24, 5357-5367.	3.0	6
44	Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy. Biomedical Optics Express, 2016, 7, 57.	2.9	50
45	The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Bioorganic and Medicinal Chemistry, 2016, 24, 5036-5046.	3.0	13
46	Pyrazolodiazepine derivatives with agonist activity toward Drosophila RYamide receptor. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5116-5118.	2.2	2
47	Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. Journal of Medicinal Chemistry, 2016, 59, 7410-7430.	6.4	34
48	Natural product derivative BIO promotes recovery after myocardial infarction via unique modulation of the cardiac microenvironment. Scientific Reports, 2016, 6, 30726.	3.3	34
49	Urinary Bladder-Relaxant Effect of Kurarinone Depending on Potentiation of Large-Conductance Ca²⁺-Activated K⁺ Channels. Molecular Pharmacology, 2016, 90, 140-150.	2.3	12
50	Contrast agent free detection of bowel perforation using chlorophyll derivatives from food plants. Chemical Physics Letters, 2016, 643, 10-15.	2.6	4
51	5-diphenylacetamido-indirubin-3â€²-oxime as a novel mitochondria-targeting agent with anti-leukemic activities. Molecular Carcinogenesis, 2016, 55, 611-621.	2.7	11
52	Homology modeling and molecular docking studies of Drosophila and Aedes sex peptide receptors. Journal of Molecular Graphics and Modelling, 2016, 66, 115-122.	2.4	5
53	Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy. , 2016, , .		1
54	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. Anticancer Research, 2016, 36, 6381-6388.	1.1	13

#	Article	IF	Citations
55	A Highly Sensitive Liquid Chromatographyâ€“Electrospray Ionizationâ€“Time of Flight/Mass Spectrometric Assay for the Quantitation of 4-Beta-Hydroxycholesterol and Its Application toin vivoCytochrome P450 3a Induction by AGM-130. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1675-1680.	1.0	2
56	Benserazide, the first allosteric inhibitor of Coxsackievirus B3 3C protease. FEBS Letters, 2015, 589, 1795-1801.	2.8	12
57	Discovery of Novel 2,5-Dioxoimidazolidine-Based P2X₇Receptor Antagonists as Constrained Analogues of KN62. Journal of Medicinal Chemistry, 2015, 58, 2114-2134.	6.4	35
58	Effects of KRC-108 on the Aurora A activity and growth of colorectal cancer cells. Biochemical and Biophysical Research Communications, 2015, 461, 605-611.	2.1	3
59	Discovery of novel purine-based heterocyclic P2X7 receptor antagonists. Bioorganic Chemistry, 2015, 61, 58-65.	4.1	1
60	Discovery and structureâ€“activity relationships of pyrazolodiazepine derivatives as the first small molecule agonists of the Drosophila sex peptide receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 1808-1816.	3.0	7
61	Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy. Bioorganic and Medicinal Chemistry, 2015, 23, 1453-1462.	3.0	41
62	Structureâ€“activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 2015, 106, 180-193.	5.5	9
63	Nanoparticle-encapsulated P2X7 receptor antagonist in a pH-sensitive polymer as a potential local drug delivery system to acidic inflammatory environments. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4197-4202.	2.2	11
64	5-Nitro-5â€²-hydroxy-indirubin-3â€²-oxime (AGM130), an indirubin-3â€²-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2015, 79, 122-131.	4.0	28
65	Solid-Phase Synthesis of Quinolinone Library. ACS Combinatorial Science, 2015, 17, 60-69.	3.8	7
66	Synthesis and therapeutic evaluation of an aptideâ€“docetaxel conjugate targeting tumor-associated fibronectin. Journal of Controlled Release, 2014, 178, 118-124.	9.9	39
67	5â€²Nitroâ€“5â€²hydroxyâ€indirubinâ€3â€²oxime Is a Novel Inducer of Somatic Cell Transdifferentiation. Archiv Der Pharmazie, 2014, 347, 806-818.	4.1	5
68	Preparation and therapeutic evaluation of paclitaxel-conjugated low-molecular-weight chitosan nanoparticles. Macromolecular Research, 2014, 22, 805-808.	2.4	10
69	Synthesized Pheophorbide aâ€mediated photodynamic therapy induced apoptosis and autophagy in human oral squamous carcinoma cells. Journal of Oral Pathology and Medicine, 2013, 42, 17-25.	2.7	40
70	Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators. European Journal of Medicinal Chemistry, 2013, 70, 811-830.	5.5	15
71	Synthesis and structureâ€“activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists. Bioorganic and Medicinal Chemistry, 2013, 21, 2643-2650.	3.0	10
72	Antiviral Activity of Coxsackievirus B3 3C Protease Inhibitor in Experimental Murine Myocarditis. Journal of Infectious Diseases, 2012, 205, 491-497.	4.0	23

#	Article	IF	Citations
73	DEVELOPMENT OF A LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD FOR THE DETERMINATION OF INDIRUBIN-5-NITRO-3â€²-MONOXIME, A NOVEL CDK INHIBITOR, IN RAT PLASMA. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 2175-2187.	1.0	1
74	Localization of a Site of Action for Benzofuroindole-Induced Potentiation of BK_{Ca} Channels. Molecular Pharmacology, 2012, 82, 143-155.	2.3	11
75	Structureâ€“Activity Relationships and Optimization of 3,5-Dichloropyridine Derivatives As Novel P2X₇ Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 3687-3698.	6.4	24
76	Development of anti-coxsackievirus agents targeting 3C protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6952-6956.	2.2	13
77	Immunosuppressive Effects of Subglutinol Derivatives. ChemMedChem, 2012, 7, 218-222.	3.2	9
78	Characterization of protoberberine analogs employed as novel human P2X7 receptor antagonists. Toxicology and Applied Pharmacology, 2011, 252, 192-200.	2.8	7
79	Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2033-2037.	2.2	36
80	MIPs are ancestral ligands for the sex peptide receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6520-6525.	7.1	147
81	5,5â€²-Substituted Indirubin-3â€²-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity. Journal of Medicinal Chemistry, 2010, 53, 3696-3706.	6.4	79
82	Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Experimental Eye Research, 2010, 91, 425-432.	2.6	93
83	Combinatorial Library Synthesis and Biological Evaluation of Pyrazolo[4,3â€e][1,4]diazepine as a Potential Privileged Structure. ChemMedChem, 2009, 4, 733-737.	3.2	16
84	Anti-tumor activity of noble indirubin derivatives in human solid tumor models In Vitro. Archives of Pharmacal Research, 2009, 32, 915-922.	6.3	27
85	Novel small molecule activators of Î²-catenin-mediated signaling pathway: structureâ€“activity relationships of indirubins. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2282-2284.	2.2	16
86	Synthesis and structureâ€“activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6053-6058.	2.2	13
87	Combinatorial synthesis and biological evaluation of peptide-binding GPCR-targeted library. Bioorganic Chemistry, 2009, 37, 90-95.	4.1	11
88	Synthesis and structureâ€“activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 954-958.	2.2	31
89	Structureâ€“activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3632-3636.	2.2	22
90	Synthesis and structureâ€“activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 571-575.	2.2	17

#	Article	IF	Citations
91	Indirubin-3â€²-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Letters, 2008, 265, 215-225.	7.2	26
92	Development of potent inhibitors of the coxsackievirus 3C protease. Biochemical and Biophysical Research Communications, 2007, 358, 7-11.	2.1	19
93	Structureâ^'Activity Relationship Studies of Spinorphin as a Potent and Selective Human P2X3Receptor Antagonist. Journal of Medicinal Chemistry, 2007, 50, 4543-4547.	6.4	31
94	Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. Bioorganic and Medicinal Chemistry, 2006, 14, 6752-6758.	3.0	15
95	Synthesis and structureâ€“activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorganic and Medicinal Chemistry, 2006, 14, 237-246.	3.0	115
96	Electrophysiological Characterization of Benzofuroindole-Induced Potentiation of Large-Conductance Ca2+-Activated K+ Channels. Molecular Pharmacology, 2006, 69, 1007-1014.	2.3	19
97	Establishment of an assay for P2X7 receptor-mediated cell death. Molecules and Cells, 2006, 22, 198-202.	2.6	5
98	Benzofuroindole Analogues as Potent BK_{Ca} Channel Openers. ChemBioChem, 2005, 6, 1745-1748.	2.6	35
99	Induction of apoptosis by a novel indirubin-5-nitro-3â€²-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3948-3952.	2.2	55
100	Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6071-6074.	2.2	20
101	Solid-Phase Synthesis of Tetrahydro-1,4-benzodiazepine-2-one Derivatives as a Î²-Turn Peptidomimetic Library. ACS Combinatorial Science, 2004, 6, 207-213.	3.3	35
102	Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. Bioorganic and Medicinal Chemistry, 2003, 11, 5059-5068.	3.0	25
103	Structureâ^'Activity Relationships of Pyridoxal Phosphate Derivatives as Potent and Selective Antagonists of P2X1Receptors. Journal of Medicinal Chemistry, 2001, 44, 340-349.	6.4	86
104	Actions of a series of PPADS analogs at P2X1 and P2X3 receptors. Drug Development Research, 2001, 53, 281-291.	2.9	24
105	Inhibition of ecto-apyrase and ecto-ATPase by pyridoxal phosphate-related compounds. Drug Development Research, 2000, 51, 153-158.	2.9	9
106	Acyclic Analogues of Deoxyadenosine 3â€˜,5â€˜-Bisphosphates as P2Y1 Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 746-755.	6.4	29
107	Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Development Research, 2000, 49, 253-259.	2.9	2
108	Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. Drug Development Research, 1999, 47, 178-188.	2.9	33

#	Article	IF	Citations
109	Synthesis and structure-activity relationships of pyridoxal-6-arylazo-5?-phosphate and phosphonate derivatives as P2 receptor antagonists. , 1998, 45, 52-66.		35
110	A3 adenosine receptors: Protective vs. damaging effects identified using novel agonists and antagonists. , 1998, 45, 113-124.		34
111	A Pyridoxine Cyclic Phosphate and Its 6-Azoaryl Derivative Selectively Potentiate and Antagonize Activation of P2X1 Receptors. Journal of Medicinal Chemistry, 1998, 41, 2201-2206.	6.4	64
112	Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS15943) Are Selective for the Human A₃Receptor Subtype. Journal of Medicinal Chemistry, 1996, 39, 4142-4148.	6.4	154